Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

doi:10.1093/infdis/171.5.1172

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

The Journal of infectious diseases - 1 May 1995

Japour A J, Welles S, D'Aquila R T, Johnson V A, Richman D D, Coombs R W, Reichelderfer P S, Kahn J O, Crumpacker C S, Kuritzkes D R

Abstract excerpt

Zidovudine resistance mutations at reverse transcriptase codons 215 or 41 were found in two-thirds of human immunodeficiency virus type 1 (HIV-1) isolates obtained at baseline from patients enrolled in an AIDS Clinical Trials Group (ACTG) protocol that compared didanosine with continued zidovudine in patients with > or = 16 weeks of previous zidovudine therapy (ACTG 116B/117). The combined presence of mutations...

Topics

Adult
Clinical Trials as Topic
Codon
DNA, Viral
Disease Progression
Drug Resistance, Microbial
Female
Genetic Markers
HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

HIV Reverse Transcriptase

HIV-1

Humans

Male

Mutation

RNA-Directed DNA Polymerase

Risk Factors

Zidovudine

Source

Open in PubMed

Identifiers

PMID: 7538548
DOI: 10.1093/infdis/171.5.1172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-7538548-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.PMID 7538548Read ↗

Correlation between antiretroviral resistance mutations, biological parameters, and clinical evolution in zidovudine-treated patients infected with human immunodeficiency virus type 1.Semantic proximity Read ↗

HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team.Semantic proximity Read ↗

Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.Semantic proximity Read ↗

Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.Semantic proximity Read ↗

Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.Semantic proximity Read ↗

Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.Semantic proximity Read ↗

Patterns of resistance mutations selected by treatment of human immunodeficiency virus type 1 infection with zidovudine, didanosine, and nevirapine.Semantic proximity Read ↗

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.Semantic proximity Read ↗

Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive personsSemantic proximity Read ↗

Short-term evolution of HIV-1 viraemia and CD4+ cell counts in patients who have a primary mutation to zidovudine.Semantic proximity Read ↗

A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.Semantic proximity Read ↗

Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.